AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
65.35
+0.91 (1.41%)
At close: Dec 20, 2024, 4:00 PM
65.46
+0.11 (0.17%)
After-hours: Dec 20, 2024, 6:25 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
$569,588
Employees
89,900
Market Cap
199.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| Novartis AG | 49.94B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Novo Nordisk | 40.47B |
AZN News
- 2 days ago - AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman - GlobeNewsWire
- 2 days ago - AstraZeneca Digital Transformation Strategy Profile 2024 - Accelerators, Incubators and Innovation Programs - GlobeNewsWire
- 3 days ago - AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 8 days ago - AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption - Hagens Berman - Accesswire
- 9 days ago - Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development - Business Wire
- 16 days ago - Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis - Business Wire
- 16 days ago - IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer - Business Wire
- 17 days ago - FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer - Reuters